Time Trends in Treatment Strategies and Survival of Older versus Younger Patients with Synchronous Metastasised Melanoma-A Population-Based Study in the Netherlands Cancer Registry

Around 45% of patients with melanoma are older than 65 years. In recent years, immunotherapy has proven very effective for metastasised melanoma. The aim of this study was to investigate the time trends in treatment strategies and survival in older versus younger patients with synchronous metastasis...

Full description

Saved in:

Bibliographic Details
Published in:	Cancers 2022-10, Vol.14 (19), p.4904
Main Authors:	van der Ziel, Daisy, Derks, Marloes G M, Kapiteijn, Ellen, Bastiaannet, Esther, Louwman, Marieke, van den Bos, Frederiek, Mooijaart, Simon P, Portielje, Johanneke E A, de Glas, Nienke A
Format:	Article
Language:	eng
Subjects:	Age Age groups Aging Cancer therapies Care and treatment Chemotherapy Demographic aspects Forecasts and trends geriatric oncology Health aspects Immunotherapy Localization Lymphatic system Melanoma Metastases Metastasis Mortality older adults Older people Patients Population Population studies Population-based studies Regression analysis Survival
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Around 45% of patients with melanoma are older than 65 years. In recent years, immunotherapy has proven very effective for metastasised melanoma. The aim of this study was to investigate the time trends in treatment strategies and survival in older versus younger patients with synchronous metastasised melanoma. We included all patients diagnosed between 2000 and 2019 from the Netherlands cancer registry. We analysed changes in first-line systemic treatment using multivariable logistic regression models, stratified by age (
ISSN:	2072-6694 2072-6694